CYB5D2
Neuferricin
Also known as: MGC32124, NEUFC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8WUJ1
- Gene
- CYB5D2
- Ensembl
- ENSG00000167740
- Chromosome
- 17
- Canonical length
- 264 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Endoplasmic reticulum,Plasma membrane
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Predicted to enable heme binding activity. Predicted to be involved in nervous system development. Predicted to act upstream of or within positive regulation of neuron differentiation. Predicted to be located in extracellular region. Predicted to be active in endomembrane system and membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
264 residues, UniProt reviewed canonical sequence.
>Q8WUJ1|CYB5D2
1 MLRCGGRGLL LGLAVAAAAV MAARLMGWWG PRAGFRLFIP EELSRYRGGP GDPGLYLALL
61 GRVYDVSSGR RHYEPGSHYS GFAGRDASRA FVTGDCSEAG LVDDVSDLSA AEMLTLHNWL
121 SFYEKNYVCV GRVTGRFYGE DGLPTPALTQ VEAAITRGLE ANKLQLQEKQ TFPPCNAEWS
181 SARGSRLWCS QKSGGVSRDW IGVPRKLYKP GAKEPRCVCV RTTGPPSGQM PDNPPHRNRG
241 DLDHPNLAEY TGCPPLAITC SFPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CYB5D2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 29 nTPM
Expression across tissuesHPA
Tissue
- parathyroid gland: 29 nTPM
- spinal cord: 27 nTPM
- epididymis: 27 nTPM
- liver: 27 nTPM
- testis: 27 nTPM
- kidney: 25 nTPM
Single-cell type
- late primary spermatocytes: 226 nCPM
- platelets: 150 nCPM
- cardiomyocytes: 134 nCPM
- epicardial cells: 123 nCPM
- early spermatids: 102 nCPM
- epididymal principal cells: 87 nCPM
Immune cell
- eosinophil: 14 nTPM
- plasmacytoid DC: 11 nTPM
- T-reg: 11 nTPM
- classical monocyte: 11 nTPM
- myeloid DC: 11 nTPM
- neutrophil: 9.6 nTPM
Brain region
- hypothalamus: 37 nTPM
- white matter: 35 nTPM
- medulla oblongata: 34 nTPM
- midbrain: 34 nTPM
- spinal cord: 33 nTPM
- pons: 33 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.46
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.61
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CYB5D2 as an antibody target. Whether an autoantibody or antibody against CYB5D2 could matter depends on whether native CYB5D2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CYB5D2 is annotated as secreted, so native CYB5D2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CYB5D2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...